Skip to content
orbyd

Dossier · OKLO · Watchlist

OKLO · Oklo Inc. · Stock research

LOW Earnings inflection Catalyst · nuclear-uranium

Last analysed ·

Current thesis

Momentum leg is dead: OKLO sliced its 52-week floor at $44.16 on 2026-07-16 to $41.03 (-79% from the Oct-2025 $193.84 peak, -28% in a month) and capital is rotating to peers. Everything now hangs on one dated binary Groves reactor criticality targeted before 2026-07-31. Miss it and the de-rating continues; hit it and a zero-revenue name finally has an operating asset.

Invalidation trigger

A weekly close below $41 (loses the 2026-07-16 capitulation low of $41.03) confirms the de-rating has no floor; secondary break if the Groves criticality target passes 2026-07-31 undelivered, or a 424B takedown lands off the $1B S-3 / $400M ATM.

Thesis status

Open commitment catalyst in 12dscored if the trigger above fires How this is scored →

Latest analysis and events for OKLO —

As of 2026-06-03, orbyd's latest analysis for Oklo Inc. (OKLO): co-founders disclosed $13.6M insider share sales (Form 4) -> -12%. Insider distribution into strength is the loudest tell on a pre-revenue name; any follow-on Form 4 = hard avoid.

Invalidation trigger: A weekly close below $41 (loses the 2026-07-16 capitulation low of $41.03) confirms the de-rating has no floor; secondary break if the Groves criticality target passes 2026-07-31 undelivered, or a 424B takedown lands off the $1B S-3 / $400M ATM.

Next dated event on file: — catalyst in 12d.

Current Thesis

The nuclear-for-AI-power trade is still alive; OKLO is no longer its expression. Shares cut through the prior 52-week floor of $44.16 on 2026-07-16 and traded down 10.2% to $41.03, roughly 79% below the $193.84 peak set in October 2025 and 28% lower in a single month. Market capitalization has compressed from about $24B at the 2025 high to roughly $7.9B against zero revenue. The de-rating is not a valuation dispute it is a credibility dispute over slipping milestone dates, and the market has stopped extending the benefit of the doubt. One dated event stands between the current tape and a genuine re-rate: the Groves Isotope Test Reactor is targeted to reach criticality before the end of July 2026, after the DOE approved its Documented Safety Analysis on 2026-07-01. That would be the first operating asset in company history. Until it lands, this is a falling knife with a death cross and a fresh 52-week low, and oversold conditions are a description of the damage rather than an entry signal.

Bullish and bearish views on Oklo Inc.

The model's bull view on Oklo Inc. (OKLO), in brief: DOE approved the Documented Safety Analysis for the Groves Isotope Test Reactor on 2026-07-01, clearing the unit into final pre-startup review with criticality targeted before 2026-07-31 a hardware milestone, not another memorandum. The bear view: The chart is structurally broken. A death cross formed in February 2026 when the 50-day crossed below the 200-day, and every rally since has failed at lower highs. The 2026-07-16 break of $44.16 removed the last reference support. Capital is rotating to peers inside the same… Both cases follow in full.

Bull Case

  • DOE approved the Documented Safety Analysis for the Groves Isotope Test Reactor on 2026-07-01, clearing the unit into final pre-startup review with criticality targeted before 2026-07-31 a hardware milestone, not another memorandum.
  • Positioning is washed out: RSI printed 28.70 on 2026-07-16 with price 19.4% below the 20-day and 48.9% below the 200-day moving average. A criticality headline into that setup has violent short-cover mechanics.
  • Vertical integration continued through the drawdown: Creative Engineers (sodium and alkali-metal process engineering, 2026-06-30) added to the ARMEC precision-manufacturing purchase (2026-06-08).
  • Fuel supply is contracted and scoped: the Centrus HALEU letter of intent (2026-06-18) covers enough domestic high-assay low-enriched uranium for up to five Aurora powerhouses over multiple years, with deliveries from 2029.
  • Bull targets have not capitulated: Cantor Overweight $122 and Wedbush Outperform $110 (both reiterated 2026-05-27), Goldman $66 (2026-05-26), against a $41 quote roughly 60% to 200% of theoretical upside if execution lands.

Bear Case

  • The chart is structurally broken. A death cross formed in February 2026 when the 50-day crossed below the 200-day, and every rally since has failed at lower highs. The 2026-07-16 break of $44.16 removed the last reference support.
  • Capital is rotating to peers inside the same theme. Cathie Wood made X-Energy a top new position (2026-07-16), and New Jersey's $24B nuclear expansion (2026-07-14) targets shovel-ready Westinghouse AP1000 units rather than SMR developers the theme's incremental dollars are bypassing this name.
  • Sell-side coverage keeps converging on the tape: Truist initiated Hold with a $55 target on 2026-07-14, Guggenheim initiated Neutral 2026-06-25, UBS cut to $55 Neutral 2026-06-11, Wolfe initiated Peer Perform 2026-05-19. Four cautious initiations in eight weeks and zero new bulls.
  • Founder distribution preceded the collapse: $13.6M of Form 4 sales disclosed 2026-06-03 drove a 12% single-day drop. Insiders monetized into strength on a company with no revenue.
  • Dilution machinery remains armed a $1B S-3 and $400M ATM stand in force while the CEI and ARMEC acquisitions consumed undisclosed cash. A 424B supplement at $41 would be materially more dilutive than one at $70.
  • Paper announcements stopped working before the price broke: shares fell on the 2026-06-16 Standard Nuclear MoU and drifted while the 2026-06-18 Centrus letter of intent rallied Centrus instead.

Setup & Price Structure

Price at $41.03 (2026-07-16, -10.2% on the session) after slicing the $44.16 prior 52-week low. The 20-day sits near $50.9 and the 200-day near $80.4 both overhead and both sloping down. The $55 shelf that Truist and UBS anchor to is now resistance, roughly 34% above spot, and the $64.99–$70.45 June insider-sale range is a distant ceiling. There is no completed base: the sequence since October 2025 is lower highs and lower lows with no higher-low reclaim at any timeframe. RSI at 28.70 flags a mechanical bounce risk for shorts but does nothing for the trend. A first constructive signal would be a higher low above $41 followed by a daily close back through $50 on expanding volume; absent that, every bid is a knife-catch and the name is a stand-aside. Averaging into weakness here is the specific behaviour that has destroyed capital in this ticker for nine months.

Catalyst Calendar (next 30 days)

  • 2026-07-31 (target, company-stated): Groves Isotope Test Reactor criticality. The single binary. Delivery = first operating milestone; a slip = the fifth missed date and confirmation the execution discount is earned.
  • ~2026-08-10 (est.): Q2 2026 results. Consensus EPS -$0.16 versus -$0.19 reported for Q1 on 2026-05-12. Zero revenue expected; the cash-burn line and any ATM usage disclosure are what matter.
  • Undated, tail risk: any 424B prospectus supplement off the $1B S-3 or $400M ATM, and any follow-on insider Form 4.

Elapsed catalysts

  • Undated, live: DOE Surplus Plutonium Utilization Program definitive agreement (advanced negotiations disclosed 2026-05-26). A signed contract is the only non-Groves upgrade path in the window. _(passed 54d ago)_

What Would Change Our Mind

Constructive: Groves reaches criticality on or before 2026-07-31 and the stock holds a higher low above $41, then closes above $50 on volume that is a narrative reset from promises to hardware and would justify a probe on the reclaim, not on the announcement wick. A signed DOE plutonium definitive agreement would compound it. Destructive: a weekly close below $41 with no criticality print by month-end confirms the de-rating has no support, and a takedown off the shelf registration at these levels would reset the share count against a shrinking equity story. Insider selling resuming after a bounce would end any bottoming case outright.

Correlation Notes

Highest beta in the advanced-nuclear basket (SMR, NNE, LEU, NuScale peers) both directions; it leads the cohort down on theme rotation and leads it up on federal-policy headlines. Correlation to uranium spot is weak this trades on regulatory and AI-datacenter power headlines, not on U3O8. Legacy nuclear (CCJ, BAM, Westinghouse exposure) is now an inverse read within the theme: the New Jersey award on 2026-07-14 sent dollars to proven AP1000 builders at SMR developers' expense. Correlation to the broad AI-power complex has loosened as datacenter-power demand headlines increasingly route to gas turbines and grid operators rather than to reactors that have not yet gone critical.

Notes

  • 2026-04-18: seed: Serenity/attention list
  • Pre-revenue: treat as event-driven, not fundamentals. Position sizing must anticipate 15%+ single-day moves.
  • Earnings blackout begins ~2026-05-08 (T-3 trading days before est. 2026-05-13 print).
  • Raise risk is acute: management has every reason to file ATM/S-3 after the record-week run. Any such filing = immediate exit, no debate.
  • NRC COLA path is the long-duration binary (2022 denial precedent). Docket acceptance = upgrade; denial/delay = thesis broken.
  • Beta to nuclear basket: highest. When cohort rotates out, Oklo leads the drop do not average down on basket weakness.
  • 2026-04-20 first red tape day post-rally is the early distribution tell. Fresh entry requires pullback + higher-low reclaim
  • not chase.
  • Pre-revenue: event-driven, not fundamentals. Size for 15%+ single-day moves in both directions.
  • 2026-06-03: co-founders disclosed $13.6M insider share sales (Form 4) -> -12%. Insider distribution into strength is the loudest tell on a pre-revenue name; any follow-on Form 4 = hard avoid.
  • Raise risk acute: post-bounce window is when pre-revenue issuers file ATM/S-3. Any 424B/S-3 = immediate exit/skip, no debate.
  • DOE Surplus Plutonium Utilization Program (5/26 advanced negotiations) is the live federal-fuel catalyst; signed definitive agreement = upgrade, lapse = thesis dent.
  • Analyst PT dispersion ~2x (Goldman $66 vs Cantor $122, May) = no fundamental anchor. Trade the tape, not the targets.
  • Beta to nuclear basket highest; leads the cohort drop on rotation. Never average down on basket weakness.
  • NRC Aurora COLA docket is an undated long-duration binary (2022 denial precedent).
  • Newcleo SPAC (5/27) = late-cycle supply / capital-competition signal for the nuclear theme; watch for rotation OUT of OKLO.
  • Q1 printed 2026-05-13 (negative reaction). Q2 est. ~mid-August. Catalyst-light window until DOE plutonium terms land.
  • 2026-06-01 insider sales: CEO Jacob DeWitte 200,000 sh + co-founder/COO Caroline Cochran $13.6M at $64.99-$70.45 (~$27M combined), under a 10b5-1 plan adopted 2025-03-31. Form 4s surfaced 2026-06-03 -> -12%. Any additional Form 4 within 2 weeks = hard avoid.
  • LIVE dilution machinery: Form S-3 for up to $1B + ATM equity distribution agreement for up to $400M with Goldman/BofA/B.Riley/TD already in force. A 424B prospectus supplement = active takedown = immediate skip/exit, no debate.
  • Price ~$58.09 on 2026-06-05: below the insider-sale range AND Goldman's $66 PT. Bounce made a lower high; structure rolled.
  • DOE Surplus Plutonium Utilization Program: advanced negotiations opened 2026-05-26. Signed definitive agreement = upgrade; lapse = thesis dent.
  • Analyst PT dispersion ~10x: low $14 / Goldman $66 / Wedbush $110 / Cantor $122 / high $140; consensus avg ~$83-89 (16 analysts, Buy, as of 2026-06-03). No fundamental anchor trade the tape, not the targets.
  • NRC Aurora COLA docket is an undated long-duration binary (2022 denial precedent). Docket acceptance = upgrade.
  • Newcleo SPAC merger (2026-05-27) = late-cycle nuclear supply / capital-competition signal; watch for rotation OUT of the group.
  • Q2 print est. ~2026-08-14; earnings blackout begins ~T-3 trading days prior.
  • Fresh entry requires a $66-$70 shelf reclaim on volume with NO new dilution filing not a chase and not a knife-catch.
  • Pre-revenue, event-driven: size for 15%+ single-day moves in both directions; trade the tape, not the targets.
  • Raise risk acute: $1B S-3 + $400M ATM armed on a pre-revenue balance sheet. Any 424B/S-3 takedown = immediate avoid, no debate.
  • Founder Form 4 sales 2026-06-03 ($13.6M, CEO DeWitte + COO Cochran) drove -12%. Any follow-on Form 4 within weeks = hard avoid.
  • Groves Isotope Test Reactor targeting first criticality in July after 2026-07-01 DOE Documented Safety Analysis approval near-term operational binary; a slip out of July dents the newest leg.
  • Highest beta in the nuclear basket; leads the cohort down on rotation. Never average down on basket weakness.
  • Analyst PT dispersion ~10x (low ~$14 to high ~$140) = no fundamental anchor. Goldman $66 / UBS $55 vs Cantor $122 / Wedbush $110.
  • Q1 printed 2026-05-13 (negative reaction). Q2 est. ~mid-August; catalyst-light on fundamentals until then.
  • NRC Aurora COLA docket is an undated long-duration binary (2022 denial precedent); docket progress = upgrade, denial/delay = thesis broken.
  • Vertical-integration string: ARMEC (2026-06-08) + Creative Engineers/CEI (2026-06-30) build in-house fuel/manufacturing chain; both cash-funded, terms undisclosed watch cash burn vs dilution.
  • Newcleo SPAC (2026-05-27) = late-cycle supply / capital-competition signal for the nuclear theme; watch for rotation OUT of OKLO.
  • Pre-revenue, event-driven. Zero fundamentals to anchor on size for 15%+ single-day moves in both directions.
  • 2026-07-31 Groves criticality is the only dated binary that matters. Delivered = first operating asset in company history; slipped = fifth missed milestone and the de-rating extends.
  • Chart is structurally broken: death cross since Feb 2026, price ~19% below the 20-DMA and ~49% below the 200-DMA as of 2026-07-16. Oversold (RSI 28.7) is not a buy signal in a confirmed downtrend.
  • Never average down on this name. Beta to the nuclear basket is the highest in the cohort and it leads the drop on rotation.
  • Insider distribution history: co-founders disclosed $13.6M of Form 4 sales 2026-06-03 (-12% day). Any follow-on Form 4 = hard avoid.
  • Raise risk acute: $1B S-3 and $400M ATM remain armed over a pre-revenue balance sheet. A 424B prospectus supplement caps any bounce.
  • Q2 print estimated ~2026-08-10 (consensus EPS -$0.16 vs Q1 actual -$0.19, printed 2026-05-12). Avoid fresh entries inside the three trading days before it.
  • Analyst dispersion is ~10x (low ~$14 / Truist $55 / UBS $55 / Goldman $66 / Wedbush $110 / Cantor $122). No fundamental anchor exists trade the tape.
  • Rotation tell: Cathie Wood built X-Energy into a top position (2026-07-16) and New Jersey's $24B nuclear program (2026-07-14) favors Westinghouse AP1000 over SMR startups. Theme capital is flowing to peers, not to OKLO.
  • NRC Aurora COLA docket remains the undated long-duration binary (2022 denial precedent).

Related · shared themes

CCJ

Cameco Corporation

The $100 shelf broke market cap $44.79B (06-29) to $38.27B (07-16), roughly $88/share, ~35% off the $135.24 January high, and it fell through the best nuclear headline flow of the cycle (NJ's $24B AP1000 plan, the $17.5B federal loan program). Barclays cut to Equal-Weight, PT $104 (07-16). Theme MATURING, structure twice-broken; nothing to do until a higher-low reclaim of ~$104. Q2 print ~2026-07-31 is the next binary.

LOW

CEG

Constellation Energy Corporation

Nuclear-for-AI narrative has broken down, not paused: -35% in H1 2026, 52-wk low $228.63 (07-01) on the Calpine lock-up release, then NY's 2026-07-14 statewide moratorium on ≥50MW data centers froze co-location upside across CEG's biggest state footprint. Sell-side targets ($296–$305) sit ~20% above spot and will be cut toward it. Stabilization story, no acceleration until the 2026-08-06 print.

LOW

NNE

Nano Nuclear Energy Inc.

Nuclear-microreactor narrative has stopped converting news into demand: a Truist Hold/$22 initiation (7/14) and a Virginia consortium announcement (7/17) landed inside four sessions and NNE still printed a fresh 52-week low at $15.78 (7/16), losing the prior $18.04 floor. Broken structure, $400M ATM armed against a ~$844M cap, first KRONOS revenue ~FY2030. Stand aside until a base forms above $22.

LOW

SMR

NuScale Power Corporation

Sovereign-capital binary: the KORUS $200B package lists nuclear among strategic sectors and reportedly eyes a NuScale reference plant, but the leg is undated and unsigned. June's ~$14 pop fully round-tripped; shares press the $8.85 52-week low with revenue -96% YoY. Sell-the-rip until a named capital figure prints alongside a real base.

LOW

See also · stocks to watch

nuclear and uranium stocks to watch